Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Photodynamic therapy approved in UK:

This article was originally published in Clinica

Executive Summary

Canadian company QLT PhotoTherapeutics has been granted marketing clearance in the UK for Photofrin (porfimer sodium), its light-activated drug treatment for late-stage lung cancer and oesophageal cancer. The drug is already available in France, Germany and the Netherlands where it is being marketed by the Vancouver-based company's partner Beafour Ipsen. It is also awaiting US approval after being backed by an FDA advisory panel in September 1998 (Clinica No 824, p 13). Photofrin is activated by non-thermal laser light produced by instruments available from a number of companies. In Europe these include lasers developed for photodynamic therapy by Laserscope, Coherent Medical Group and Diomed.

You may also be interested in...

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

COVID-19 Serology Templates: FDA Updates Sponsor Template, Adds Home Test Document

The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts